ATE262584T1 - Verwendung eines inhibitors von tau/neurofilament-proteinkinase pk40 - Google Patents

Verwendung eines inhibitors von tau/neurofilament-proteinkinase pk40

Info

Publication number
ATE262584T1
ATE262584T1 AT00104460T AT00104460T ATE262584T1 AT E262584 T1 ATE262584 T1 AT E262584T1 AT 00104460 T AT00104460 T AT 00104460T AT 00104460 T AT00104460 T AT 00104460T AT E262584 T1 ATE262584 T1 AT E262584T1
Authority
AT
Austria
Prior art keywords
tau
kinases
protein kinase
kinase inhibitor
neurofilament protein
Prior art date
Application number
AT00104460T
Other languages
English (en)
Inventor
Vernon M Ingram
Hanno M Roder
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of ATE262584T1 publication Critical patent/ATE262584T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00104460T 1991-08-09 1992-07-10 Verwendung eines inhibitors von tau/neurofilament-proteinkinase pk40 ATE262584T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74288091A 1991-08-09 1991-08-09

Publications (1)

Publication Number Publication Date
ATE262584T1 true ATE262584T1 (de) 2004-04-15

Family

ID=24986618

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00104460T ATE262584T1 (de) 1991-08-09 1992-07-10 Verwendung eines inhibitors von tau/neurofilament-proteinkinase pk40
AT92915162T ATE206755T1 (de) 1991-08-09 1992-07-10 Verwendungen einer proteinkinase von ton und neurofilament pk40

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT92915162T ATE206755T1 (de) 1991-08-09 1992-07-10 Verwendungen einer proteinkinase von ton und neurofilament pk40

Country Status (9)

Country Link
EP (2) EP1026237B1 (de)
JP (1) JPH06510427A (de)
AT (2) ATE262584T1 (de)
AU (1) AU675410B2 (de)
CA (1) CA2115151C (de)
DE (2) DE69233330T2 (de)
DK (2) DK1026237T3 (de)
ES (2) ES2216745T3 (de)
WO (1) WO1993003148A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
ATE386115T1 (de) * 1991-12-06 2008-03-15 Max Planck Gesellschaft Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit
US6107472A (en) * 1992-05-11 2000-08-22 Ludwig Institute For Cancer Research Receptor-type tyrosine kinase-like molecules
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
KR20030022265A (ko) * 2000-07-07 2003-03-15 밀리켄 앤드 캄파니 지속가능한 발수능 및 오염제거능이 개선된 텍스타일 기재및 이의 제조방법
US7790881B2 (en) 2004-09-23 2010-09-07 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
CN108034005B (zh) * 2011-10-07 2021-06-25 Ac免疫有限公司 识别Tau的磷酸化特异抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920703068A (ko) * 1989-09-15 1992-12-17 폴 레이킨드 신경변성 질환의 치료방법
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
WO1993003177A1 (en) * 1991-08-09 1993-02-18 Massachusetts Institute Of Technology Novel tau/neurofilament protein kinases
EP0544942A1 (de) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Neue Werkzeuge für die Diagnose und die Behandlung der Alzheimer-Krankheit

Also Published As

Publication number Publication date
DE69232121D1 (de) 2001-11-15
EP0667898B1 (de) 2001-10-10
AU675410B2 (en) 1997-02-06
DE69233330T2 (de) 2005-03-10
CA2115151C (en) 2005-05-17
ES2216745T3 (es) 2004-11-01
EP0667898A1 (de) 1995-08-23
JPH06510427A (ja) 1994-11-24
CA2115151A1 (en) 1993-02-18
EP1026237A3 (de) 2001-03-28
ES2165358T3 (es) 2002-03-16
ATE206755T1 (de) 2001-10-15
EP1026237B1 (de) 2004-03-24
DE69232121T2 (de) 2002-06-20
EP1026237A2 (de) 2000-08-09
WO1993003148A2 (en) 1993-02-18
DK1026237T3 (da) 2004-07-19
DE69233330D1 (de) 2004-04-29
WO1993003148A3 (en) 1993-04-01
DK0667898T3 (da) 2002-02-04
AU2324092A (en) 1993-03-02

Similar Documents

Publication Publication Date Title
ATE231505T1 (de) Neue heterocyclische/cyclische amine
IE892272L (en) Novel fused heterocyclic compounds
DE69627179T2 (de) Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
FI945706A7 (fi) Proteiinikinaasi C-inhibiittoreita
DK0648838T3 (da) Vævsinhibitor af metalloproteinase type tre (TIMP-3)
DE10299011I1 (de) Interleukin-1-Inhibitoren
ATE161536T1 (de) Neue mercaptoacetylamid-derivate zur verwendung als enkephalinase- und ace-hemmer
EA199700186A1 (ru) Новые дипептидные амидины, используемые в качестве ингибиторов тромбина
DK0788356T3 (da) Fremgangsmåde og præparater til hæmning af proteinkinaser
NO962188L (no) Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav
DE69011119D1 (de) Magnetkopf-aufhaengevorrichtung zur verwendung bei photographischen filmen.
NO944406D0 (no) Nye 7 se inhibitorer
PT83535B (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de aminoacidos
ATE110074T1 (de) Quinolyloxazol-2-one, nützlich als proteinkinase- c-inhibitoren.
ATE262584T1 (de) Verwendung eines inhibitors von tau/neurofilament-proteinkinase pk40
EP0617335A3 (de) Direktes Aufzeichnungsverfahren.
DE3881538D1 (de) Verwendung eines klebstoffes zur palettisierung.
NO305556B1 (no) Tiokarbamoylforbindelser og anvendelse derav samt middel for beskyttelse av tekniske materialer
DE69206001D1 (de) Verfahren zur hochsensitiven Bestimmung von NADH mit NADH Kinase.
MX9700116A (es) Uso de leucotriarilmetanos para la marcacion de hidrocarburos.
SU1783778A1 (ru) Производные 4-(1-окси-1-аминокарбонил-2,2,2-трифторэтил)-n-этиланилинов, обладающие антидотной активностью к хлорсульфурону

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1026237

Country of ref document: EP

REN Ceased due to non-payment of the annual fee